Profile: MIV Therapeutics, Inc manufactures a line of ultra thin, polymer-free passive & drug-eluting coatings for cardiovascular stents and other implantable medical devices. Our product line includes surface modification & drug delivery and drug-eluting stents. Our surface modification stents include nanofilm hydroxyapatite surface modification or coating, macroporous hydroxyapatite surface modification or coating and polymer-free lipid-based drug eluting and encapsulation formulations. Our drug-eluting stents successfully counter measured post-deployment inflammatory reactions and considerably reduce the incidence of restenosis to only approximately 8% from 25% experienced with leading bare metal stents. The stents are tiny wire-mesh tubes made of surgical grade stainless steel, cobalt, chromium, or other metal alloys designed to keep arteries open. The stent material is not native to the body and its presence in a vascular environment incites an immune response. This response often demonstrates itself in abnormal cell proliferation resulting in the scar tissue excessively overgrowing the stent.

The company was founded in 1999, has revenues of < USD 1 Million, has ~10 employees. OTC:MIVT (SEC Filings)